Neuraminidase inhibitors for influenza complications: Authors' reply

The Lancet

Volumn 384, Issue 9950, 2014, Pages 1261-1262

  Nguyen Van Tam, Jonathan S ^a   Openshaw, Peter J M ^b   Nicholson, Karl G ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ANTIVIRUS AGENT; SIALIDASE;

2009 H1N1 INFLUENZA; FLU LIKE SYNDROME; HOSPITAL ADMISSION; HUMAN; INFLUENZA; LETTER; MORTALITY; PANDEMIC INFLUENZA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; INFLUENZA, HUMAN;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE;

EID: 84923321517     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61762-1     Document Type: Letter

References (5)

1. Nguyen-Van-Tam JS, Openshaw PJ, Nicholson KG. Antivirals for infl uenza: where now for clinical practice and pandemic preparedness? Lancet 2014; 384: 386-87.
2. Jeff erson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating infl uenza in healthy adults and children. Cochrane Database Syst Rev 2014; 4: CD008965.
3. Muthuri SG, Venkatesan S, Myles PR, et al, for the PRIDE Consortium Investigators, Nguyen-Van-Tam JS. Eff ectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with infl uenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2: 395-404.
4. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on infl uenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667-72.
5. Chalmers I. The development of fair tests of treatments. Lancet 2014; 383: 1713-14.